Samsung Invests $10 Million In C2N Diagnostics To Scale Clinical Lab Services For Brain Health Diagnostic Solutions

C2N Diagnostics, LLC (C2N), a specialty diagnostics company, received a $10 million investment from Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation (Samsung). Through this strategic investment, C2N aims to continue accelerating organizational capabilities, clinical laboratory services, and diagnostic solutions to ensure that consumers globally have access to C2N’s blood biomarker testing technologies for Alzheimer’s disease and related dementias.

C2N developed and markets the PrecivityAD2™ blood test algorithm to improve the diagnostic accuracy of Alzheimer’s disease in primary care settings. A large clinical study examining the test’s accuracy found the . . .